tezacaftor

Also known as VX-661

Tezacaftor is a medication used for the treatment of cystic fibrosis. It is available in fixed-dose combination medications.

Chemical data

Formula: C26H27F3N2O6
Molecular weight: 520.5 g/mol
IUPAC name: 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide
SMILES: CC(C)(CO)C1=CC2=CC(=C(C=C2N1C[C@H](CO)O)F)NC(=O)C3(CC3)C4=CC5=C(C=C4)OC(O5)(F)F
InChIKey: MJUVRTYWUMPBTR-MRXNPFEDSA-N
XLogP: 2.9
Polar surface area: 113 Å²
H-bond donors: 4
H-bond acceptors: 9
Formal charge: 0

via PubChem

Drug data · ChEMBL

Max clinical phase: Approved
Molecule type: Small molecule
First approval: 2018
Admin. routes: oral
Indications: cystic fibrosis

via ChEMBL · EBI

Wikidata facts

Subclass of: chemical compound
Mass: 520.182
Has use: medication

Show 4 more facts

canonical SMILES: CC(C)(CO)C1=CC2=CC(=C(C=C2N1CC(CO)O)F)NC(=O)C3(CC3)C4=CC5=C(C=C4)OC(O5)(F)F
chemical formula: C₂₆H₂₇F₃N₂O₆
isomeric SMILES: CC(C)(CO)C1=CC2=CC(=C(C=C2N1C[C@H](CO)O)F)NC(=O)C3(CC3)C4=CC5=C(C=C4)OC(O5)(F)F
Commons category: Tezacaftor

Sources (2)

via Wikidata · CC0

~3 min read

Encyclopedic overview

7 sections

Contents

Mechanism of action
Clinical trials
EVOLVE trial
History
Society and culture
Names
References

Tezacaftor is a medication used for the treatment of cystic fibrosis. It is available in fixed-dose combination medications.

The combination of tezacaftor with ivacaftor (brand name Symdeko) was approved for medical use in the United States in February 2018, and in Canada in June 2018. As brand name Symkevi it was approved for medical use in the European Union in October 2018.

Excerpted from Wikipedia’s “tezacaftor” article, available under the CC BY-SA 4.0 licence.